{"transactions":[{"id":2211305,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2022-07-06T23:19:52.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":31746,"price":3.15,"value":99999.9,"ownership":{"direct":true},"balance_after":31746,"source":{"system":"sec-edgar","filing":"0000899243-22-025506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322025506/doc4.xml","form_type":"4"}},{"id":2221783,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:35:37.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-22-024010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322024010/doc4.xml","form_type":"4"}},{"id":2221781,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:32:18.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-22-023992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322023992/doc4.xml","form_type":"4"}},{"id":2659995,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T20:30:17.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders."}],"balance_after":23000,"derivative":{"exercise_price":19.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000899243-21-024989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924321024989/doc4.xml","form_type":"4"}},{"id":3102748,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T20:12:21.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders."}],"balance_after":30000,"derivative":{"exercise_price":4.4,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924320017355/doc4.xml","form_type":"4"}},{"id":3159654,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:09:24.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":16,"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001694187-20-000072","document":"wf-form4_158881374542545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000072/wf-form4_158881374542545.xml","form_type":"4"}},{"id":3159653,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:09:24.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":9.65,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001694187-20-000072","document":"wf-form4_158881374542545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000072/wf-form4_158881374542545.xml","form_type":"4"}},{"id":3159652,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:09:24.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":18500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":4.64,"underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001694187-20-000072","document":"wf-form4_158881374542545.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000072/wf-form4_158881374542545.xml","form_type":"4"}},{"id":3476924,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-27T08:28:19.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 25, 2019 with respect to 18,500 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":18500,"derivative":{"exercise_price":4.64,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001694187-19-000054","document":"wf-form4_156163848249549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418719000054/wf-form4_156163848249549.xml","form_type":"4"}},{"id":3489030,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T20:08:44.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":2.83,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-017010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924319017010/doc4.xml","form_type":"4"}},{"id":3826985,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":125553,"kind":"person","name":"Zausner Meryl","position":1,"cik":"0001742142","reported_name":"Zausner Meryl","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-09-04T20:49:38.000Z","date":"2018-08-30","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in four equal installments on each anniversary of 08/30/2018 or in full immediately prior to the occurrence of a change in control."}],"balance_after":30000,"derivative":{"exercise_price":8.47,"expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-18-023729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318023729/doc4.xml","form_type":"4"}}]}